Revenio Group Oyj — Director's Dealing 2022

May 11, 2022

Revenio Group Corporation: Managers' Transactions – Riad Sherif

Revenio Group Corporation: Managers' Transactions – Riad Sherif

Revenio Group Corporation, Managers’ transactions, May 11, 2022 at 3.00 p.m. (EEST)

Revenio Group Corporation: Managers' Transactions – Riad Sherif

____________________________________________

Person subject to the notification requirement

Name: Riad Sheriff

Position: Member of the Board/Deputy member

Issuer: Revenio Group Oyj

LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION

Reference number: 14610/7/6

____________________________________________

Transaction date: 2022-05-11

Venue not applicable

Instrument type: SHARE

ISIN: FI0009010912

Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details

(1): Volume: 300 Unit price: 0 N/A

Aggregated transactions

(1): Volume: 300 Volume weighted average price: 0 N/A

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

Distribution

Nasdaq Helsinki Ltd

Main media

www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare software solutions provide eye care professionals with new innovative digital clinical tools that drive greater efficiency and enhance the quality of care.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments: